Skip to navigation Skip to content



Negative Results from Phase 2 Clinical Trial of Laquinimod in Primary Progressive MS

December 1, 2017

A phase 2 clinical trial of oral laquinimod in people with primary progressive MS did not meet its primary endpoint of slowing brain atrophy (shrinkage) after 48 weeks, and did not slow progression of disability. The results were announcement by Active Biotech, a company that has been partnering with Teva Pharmaceuticals Industries in the development of Laquinimod.
“This is disappointing news,” noted Bruce Bebo, PhD, Executive Vice President of Research at the National MS Society. “The treatment landscape is changing with the first therapy for primary progressive MS approved in 2017, but we still have a long way to go to find solutions for everyone living with MS.”
Additional details will be published and presented at a future medical conference.

About Multiple Sclerosis

Multiple sclerosis is an unpredictable, often disabling disease of the central nervous system that disrupts the flow of information within the brain, and between the brain and body. Symptoms range from numbness and tingling to blindness and paralysis. The progress, severity and specific symptoms of MS in any one person cannot yet be predicted, but advances in research and treatment are leading to better understanding and moving us closer to a world free of MS. Most people with MS are diagnosed between the ages of 20 and 50, with at least two to three times more women than men being diagnosed with the disease. MS affects more than 2.3 million people worldwide.


© 2020 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization and our Identification Number (EIN) is 13-5661935.